These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 10714659)
1. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Fox NC; Cousens S; Scahill R; Harvey RJ; Rossor MN Arch Neurol; 2000 Mar; 57(3):339-44. PubMed ID: 10714659 [TBL] [Abstract][Full Text] [Related]
2. Combining short interval MRI in Alzheimer's disease: Implications for therapeutic trials. Schott JM; Frost C; Whitwell JL; Macmanus DG; Boyes RG; Rossor MN; Fox NC J Neurol; 2006 Sep; 253(9):1147-53. PubMed ID: 16998650 [TBL] [Abstract][Full Text] [Related]
3. Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease. Bradley KM; Bydder GM; Budge MM; Hajnal JV; White SJ; Ripley BD; Smith AD Br J Radiol; 2002 Jun; 75(894):506-13. PubMed ID: 12124237 [TBL] [Abstract][Full Text] [Related]
4. Measuring atrophy in Alzheimer disease: a serial MRI study over 6 and 12 months. Schott JM; Price SL; Frost C; Whitwell JL; Rossor MN; Fox NC Neurology; 2005 Jul; 65(1):119-24. PubMed ID: 16009896 [TBL] [Abstract][Full Text] [Related]
5. Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. Fox NC; Freeborough PA J Magn Reson Imaging; 1997; 7(6):1069-75. PubMed ID: 9400851 [TBL] [Abstract][Full Text] [Related]
6. Common MRI acquisition non-idealities significantly impact the output of the boundary shift integral method of measuring brain atrophy on serial MRI. Preboske GM; Gunter JL; Ward CP; Jack CR Neuroimage; 2006 May; 30(4):1196-202. PubMed ID: 16380273 [TBL] [Abstract][Full Text] [Related]
7. Sample Size Estimation for Alzheimer's Disease Trials from Japanese ADNI Serial Magnetic Resonance Imaging. Fujishima M; Kawaguchi A; Maikusa N; Kuwano R; Iwatsubo T; Matsuda H; ; J Alzheimers Dis; 2017; 56(1):75-88. PubMed ID: 27911297 [TBL] [Abstract][Full Text] [Related]
8. MRI derived brain atrophy in PSP and MSA-P. Determining sample size to detect treatment effects. Paviour DC; Price SL; Lees AJ; Fox NC J Neurol; 2007 Apr; 254(4):478-81. PubMed ID: 17401522 [TBL] [Abstract][Full Text] [Related]
10. Application of automated medial temporal lobe atrophy scale to Alzheimer disease. Ridha BH; Barnes J; van de Pol LA; Schott JM; Boyes RG; Siddique MM; Rossor MN; Scheltens P; Fox NC Arch Neurol; 2007 Jun; 64(6):849-54. PubMed ID: 17562933 [TBL] [Abstract][Full Text] [Related]
11. Comparisons between global and focal brain atrophy rates in normal aging and Alzheimer disease: Boundary Shift Integral versus tracing of the entorhinal cortex and hippocampus. Ezekiel F; Chao L; Kornak J; Du AT; Cardenas V; Truran D; Jagust W; Chui H; Miller B; Yaffe K; Schuff N; Weiner M Alzheimer Dis Assoc Disord; 2004; 18(4):196-201. PubMed ID: 15592130 [TBL] [Abstract][Full Text] [Related]
12. Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Leung KK; Clarkson MJ; Bartlett JW; Clegg S; Jack CR; Weiner MW; Fox NC; Ourselin S; Neuroimage; 2010 Apr; 50(2):516-23. PubMed ID: 20034579 [TBL] [Abstract][Full Text] [Related]
13. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Jack CR; Slomkowski M; Gracon S; Hoover TM; Felmlee JP; Stewart K; Xu Y; Shiung M; O'Brien PC; Cha R; Knopman D; Petersen RC Neurology; 2003 Jan; 60(2):253-60. PubMed ID: 12552040 [TBL] [Abstract][Full Text] [Related]
14. Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals. Hua X; Lee S; Hibar DP; Yanovsky I; Leow AD; Toga AW; Jack CR; Bernstein MA; Reiman EM; Harvey DJ; Kornak J; Schuff N; Alexander GE; Weiner MW; Thompson PM; Neuroimage; 2010 May; 51(1):63-75. PubMed ID: 20139010 [TBL] [Abstract][Full Text] [Related]
16. Normative estimates of cross-sectional and longitudinal brain volume decline in aging and AD. Fotenos AF; Snyder AZ; Girton LE; Morris JC; Buckner RL Neurology; 2005 Mar; 64(6):1032-9. PubMed ID: 15781822 [TBL] [Abstract][Full Text] [Related]
17. Correlation between rates of brain atrophy and cognitive decline in AD. Fox NC; Scahill RI; Crum WR; Rossor MN Neurology; 1999 May; 52(8):1687-9. PubMed ID: 10331700 [TBL] [Abstract][Full Text] [Related]
18. Mapping hippocampal and ventricular change in Alzheimer disease. Thompson PM; Hayashi KM; De Zubicaray GI; Janke AL; Rose SE; Semple J; Hong MS; Herman DH; Gravano D; Doddrell DM; Toga AW Neuroimage; 2004 Aug; 22(4):1754-66. PubMed ID: 15275931 [TBL] [Abstract][Full Text] [Related]
19. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Teipel SJ; Grothe M; Lista S; Toschi N; Garaci FG; Hampel H Med Clin North Am; 2013 May; 97(3):399-424. PubMed ID: 23642578 [TBL] [Abstract][Full Text] [Related]
20. Responsiveness of magnetic resonance imaging and neuropsychological assessment in memory clinic patients. Schmand B; Rienstra A; Tamminga H; Richard E; van Gool WA; Caan MW; Majoie CB J Alzheimers Dis; 2014; 40(2):409-18. PubMed ID: 24473187 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]